Sign in
CompletedPhase 2

Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia

Key facts

Who runs it
Institut de Cancérologie de Lorraine
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
17 people enrolled
Started
29 Nov 2021
Ended
25 May 2025
Type of study
Interventional
Treatments tested
  • Metvixia Topical Cream
Record updated
24 July 2025

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patient aged 18 and over,
  • With isolated high-grade vulvar intraepithelial neoplasia OR associated with invasive cancer proven histologically by biopsy
  • Naive of any vulvovaginal treatment (surgery or radiotherapy)
  • No metastases
  • WHO <or equal to 3
  • Contraception method for women of childbearing potential
  • Patient affiliated to the social security scheme
  • Patient who understood, signed and dated the information note and the
  • consent form,
  • Patient able and willing to follow all study procedures in accordance with the protocol

Who cannot take part

  • Any previous vulvovaginal treatment (surgery or radiotherapy)
  • Associated pathology that may prevent the patient from receiving METVIXIA application and light exposure
  • History of hypersensitivity to the active substance methyl aminolevulinate or to any of the components of the drug (including peanut oil and refined almond oil), soybean or peanut
  • Metastatic disease
  • Patient undergoing treatment for any other invasive cancer
  • Ulceration or hyperpigmented lesions of the vulva
  • Patient with porphyria
  • Pregnant, likely to be or breastfeeding patient
  • Patient deprived of liberty or under guardianship (including guardianship)
  • Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons
  • Patient already included in another therapeutic trial with an experimental molecule,

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a single-center propsective clinical trial to assess the ability of fluorescence techniques to mark high-grade vulvar intraepithelial neoplasias including high-grade vulvar squamous intraepithelial lesions and differentiated vulvar intraepithelial neoplasias following 3 hours Metvixia application.

The group in the trial

  • Metvixia application for Photodynamic diagnosisTreatment being tested

    Patients who benefit Metvixia application to the vulva to realize fluorescence guided biopsies (Photodynamic diagnosis).

    Treatment: Metvixia Topical Cream

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Ability of PpIX Fluorescence to Mark High-grade Vulvar Intraepithelial Neoplasia Following the Methyl Aminolevulinate (Metvixia®) Application
Record updated
24 July 2025